Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone

Marimu Sakumoto, Mami Takahashi, Rieko Oyama, Yoko Takai, Fusako Kito, Kumiko Shiozawa, Zhiwei Qiao, Akihiko Yoshida, Makoto Endo, Akira Kawai, Tadashi Kondo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental models such as patient-derived cell lines are invaluable tools for pre-clinical studies. In the present study, we established a stable cell line from the tumor tissue of a patient with a primary LMS of the bone. Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which are primary to the bone. Methods: Bone primary LMS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to pazopanib was evaluated. Results: NCC-LMS1-C1 cells were maintained for over 100 passages. The cells exhibited a spindle shape and aggressive growth; they also expressed smooth muscle actin, reflecting the original LMS tissue (i.e. smooth muscle cells). The cells also showed tumor characteristics such as colony formation on soft agar and sensitivity to pazopanib, doxorubicin and cisplatin, with half-maximal inhibitory concentrations of 4.5, 0.11 and 20 μM, respectively. Proteomic analyses by mass spectrometry and antibody array revealed some differences in the protein expression profiles of these cells as compared to the original tumor tissue. Conclusions: Our results indicate that the NCC-LMS1-C1 cell lines will be useful for LMS research.

Original languageEnglish
Pages (from-to)954-961
Number of pages8
JournalJapanese journal of clinical oncology
Volume47
Issue number10
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Leiomyosarcoma
Proteomics
Bone and Bones
Cell Line
Smooth Muscle
Neoplasms
Tumor Cell Line
Doxorubicin
Cisplatin
Agar
Smooth Muscle Myocytes
Actins
Mass Spectrometry
Theoretical Models
Antibodies
Therapeutics
Growth
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone. / Sakumoto, Marimu; Takahashi, Mami; Oyama, Rieko; Takai, Yoko; Kito, Fusako; Shiozawa, Kumiko; Qiao, Zhiwei; Yoshida, Akihiko; Endo, Makoto; Kawai, Akira; Kondo, Tadashi.

In: Japanese journal of clinical oncology, Vol. 47, No. 10, 01.10.2017, p. 954-961.

Research output: Contribution to journalArticle

Sakumoto, M, Takahashi, M, Oyama, R, Takai, Y, Kito, F, Shiozawa, K, Qiao, Z, Yoshida, A, Endo, M, Kawai, A & Kondo, T 2017, 'Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone', Japanese journal of clinical oncology, vol. 47, no. 10, pp. 954-961. https://doi.org/10.1093/jjco/hyx096
Sakumoto, Marimu ; Takahashi, Mami ; Oyama, Rieko ; Takai, Yoko ; Kito, Fusako ; Shiozawa, Kumiko ; Qiao, Zhiwei ; Yoshida, Akihiko ; Endo, Makoto ; Kawai, Akira ; Kondo, Tadashi. / Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone. In: Japanese journal of clinical oncology. 2017 ; Vol. 47, No. 10. pp. 954-961.
@article{972910ea1df34322aafa3768f1bc161c,
title = "Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone",
abstract = "Background: Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental models such as patient-derived cell lines are invaluable tools for pre-clinical studies. In the present study, we established a stable cell line from the tumor tissue of a patient with a primary LMS of the bone. Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which are primary to the bone. Methods: Bone primary LMS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to pazopanib was evaluated. Results: NCC-LMS1-C1 cells were maintained for over 100 passages. The cells exhibited a spindle shape and aggressive growth; they also expressed smooth muscle actin, reflecting the original LMS tissue (i.e. smooth muscle cells). The cells also showed tumor characteristics such as colony formation on soft agar and sensitivity to pazopanib, doxorubicin and cisplatin, with half-maximal inhibitory concentrations of 4.5, 0.11 and 20 μM, respectively. Proteomic analyses by mass spectrometry and antibody array revealed some differences in the protein expression profiles of these cells as compared to the original tumor tissue. Conclusions: Our results indicate that the NCC-LMS1-C1 cell lines will be useful for LMS research.",
author = "Marimu Sakumoto and Mami Takahashi and Rieko Oyama and Yoko Takai and Fusako Kito and Kumiko Shiozawa and Zhiwei Qiao and Akihiko Yoshida and Makoto Endo and Akira Kawai and Tadashi Kondo",
year = "2017",
month = "10",
day = "1",
doi = "10.1093/jjco/hyx096",
language = "English",
volume = "47",
pages = "954--961",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone

AU - Sakumoto, Marimu

AU - Takahashi, Mami

AU - Oyama, Rieko

AU - Takai, Yoko

AU - Kito, Fusako

AU - Shiozawa, Kumiko

AU - Qiao, Zhiwei

AU - Yoshida, Akihiko

AU - Endo, Makoto

AU - Kawai, Akira

AU - Kondo, Tadashi

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental models such as patient-derived cell lines are invaluable tools for pre-clinical studies. In the present study, we established a stable cell line from the tumor tissue of a patient with a primary LMS of the bone. Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which are primary to the bone. Methods: Bone primary LMS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to pazopanib was evaluated. Results: NCC-LMS1-C1 cells were maintained for over 100 passages. The cells exhibited a spindle shape and aggressive growth; they also expressed smooth muscle actin, reflecting the original LMS tissue (i.e. smooth muscle cells). The cells also showed tumor characteristics such as colony formation on soft agar and sensitivity to pazopanib, doxorubicin and cisplatin, with half-maximal inhibitory concentrations of 4.5, 0.11 and 20 μM, respectively. Proteomic analyses by mass spectrometry and antibody array revealed some differences in the protein expression profiles of these cells as compared to the original tumor tissue. Conclusions: Our results indicate that the NCC-LMS1-C1 cell lines will be useful for LMS research.

AB - Background: Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental models such as patient-derived cell lines are invaluable tools for pre-clinical studies. In the present study, we established a stable cell line from the tumor tissue of a patient with a primary LMS of the bone. Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which are primary to the bone. Methods: Bone primary LMS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to pazopanib was evaluated. Results: NCC-LMS1-C1 cells were maintained for over 100 passages. The cells exhibited a spindle shape and aggressive growth; they also expressed smooth muscle actin, reflecting the original LMS tissue (i.e. smooth muscle cells). The cells also showed tumor characteristics such as colony formation on soft agar and sensitivity to pazopanib, doxorubicin and cisplatin, with half-maximal inhibitory concentrations of 4.5, 0.11 and 20 μM, respectively. Proteomic analyses by mass spectrometry and antibody array revealed some differences in the protein expression profiles of these cells as compared to the original tumor tissue. Conclusions: Our results indicate that the NCC-LMS1-C1 cell lines will be useful for LMS research.

UR - http://www.scopus.com/inward/record.url?scp=85030667731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030667731&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx096

DO - 10.1093/jjco/hyx096

M3 - Article

C2 - 28981730

AN - SCOPUS:85030667731

VL - 47

SP - 954

EP - 961

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -